Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
about
Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitorExpression of the secretory leukoprotease inhibitor gene in epithelial cellsAnti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitorHuman mast cells decrease SLPI levels in type II - like alveolar cell model, in vitroThe Role of Serine Proteases and Antiproteases in the Cystic Fibrosis LungComplex of human neutrophil elastase with 1/2SLPIStructure basis 1/2SLPI and porcine pancreas trypsin interactionSecretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitroSecretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrateSecretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritisAnti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.The transcriptome of Trichuris suis--first molecular insights into a parasite with curative properties for key immune diseases of humans.Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozymeAnti-HIV-1 activity of elafin depends on its nuclear localization and altered innate immune activation in female genital epithelial cells.Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice.Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cellsParacrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cellsThe inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps.Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.Tumor necrosis factor-alpha (TNF-α) is a therapeutic target for impaired cutaneous wound healing.Inhibition by recombinant SLPI and half-SLPI (Asn55-Ala107) of elastase and cathepsin G activities: consequence for neutrophil-platelet cooperation.Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidantsNovel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis.Activated microglia enhance neurogenesis via trypsinogen secretion.Secretory leukocyte protease inhibitor reverses inhibition by CNS myelin, promotes regeneration in the optic nerve, and suppresses expression of the transforming growth factor-β signaling protein Smad2.Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis.Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5-triphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease.Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases.Innate immune effectors in mycobacterial infection.The Ability of Secretory Leukocyte Protease Inhibitor to Inhibit Apoptosis in Monocytes Is Independent of Its Antiprotease Activity.Antibacterial activity of antileukoprotease.Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor.Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor.Expression and characterization of recombinant human secretory leukocyte protease inhibitor (SLPI) protein from Pichia pastoris.Interaction between secretory leucocyte proteinase inhibitor and bronchial mucins or glycopeptides. Physiopathological implications for the protection of mucins against proteolysis by human leucocyte elastase.Heparin accelerates the inhibition of cathepsin G by mucus proteinase inhibitor: potent effect of O-butyrylated heparin.Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema.
P2860
Q24303274-3D357A3A-B9BA-4D2D-A5DE-9B3F4B6A9DB5Q24617821-D8EB961A-983F-47C2-8B94-8FF30A1ED6D2Q24681571-D4FA3EF7-86C7-41C3-A60D-ECD69B8F8825Q24799057-AA056D38-BD8B-48D0-8A36-9207B7DB11CDQ26799771-FF62FE8D-B894-4AD9-9F8F-A67861384870Q27650385-691E159D-617D-4032-ADD1-CEDE7BC50CE8Q27680269-A838C0F2-E2A4-45B8-AFA9-C071BB6C0A20Q28293679-9A237784-F348-4EC4-81C8-46B9C37FE8CBQ28478487-3E153E1B-3500-4AD7-866D-C68069886691Q28572864-158E7DE9-80C8-4BB9-B7E9-C6A34597EEAEQ33715960-954D9A15-69B0-4E25-8506-85FC18C14BBBQ34009430-4D98D8D0-54F7-4A98-A291-41BD6A979D75Q34130420-C30FE198-EE5A-428B-8B3A-8A4A7EFB4986Q34541093-5E80EE04-8810-4FA2-95A0-8A9E8C4CF928Q35014657-A1D9B6C4-EE7D-4CF2-A7CE-9D764EC0900CQ35022070-315C6873-2691-4AEA-8961-8AED619F7F4BQ35154168-36F073B9-8805-4180-A4D3-3DC6E8C9DFDAQ35741744-38DC22E2-3185-49ED-BEC9-7F621B2F0E7EQ35764264-B2E96D89-BD90-4A06-B3C8-D1D6E81A2AF6Q35779604-76333F60-BC06-4D8C-BF7B-7AAA026D682DQ35871662-7AF63668-1F00-4A20-9EFB-9859E4F42206Q35920633-A02F1B6B-D5A7-468E-92D3-74D44E1B97C7Q36104532-FABD593F-2347-458F-B3AC-D445BB19EDBFQ36735031-5ACD4A64-E7F9-4035-989B-BC76C62FDC80Q36884025-DC5ED7F9-989D-425E-895E-0BDCC52B907FQ36934092-527527FF-B47D-428C-9F51-0A0B05416315Q36945415-2B7439A5-D503-4042-9114-D0F05BA6D4FFQ37114356-71DEB23C-DDA9-4EBE-98A9-D5F01E78D6C7Q37116400-2289405C-FEC2-40BC-8656-7B96AFA8B9A9Q37171832-48BF8A4B-7748-4AFE-9EF6-9CF071A8C509Q37364288-2855BC5F-4AE7-40BE-97BD-A8190C0C2504Q37832959-4C8F00C4-A572-484B-8F10-8E323A4D8B7EQ38845999-F20DEA58-3EC2-4FC3-A29D-0EB0D4A2E498Q39826482-CA394E22-AC40-499D-BFFC-453D5A9FE676Q40983959-92E87463-9100-4E98-B786-A139D73C2E7AQ41841309-D7F831F8-854B-4A4E-89FB-6BCE84F2DC5FQ42575864-7600132F-F763-434D-8B52-065490EE3AD7Q42725372-1C4C6CF9-B5E1-4060-ABBC-10748CFF6262Q42989967-1AD5AAA3-83AB-484C-A255-52ED5344F9B8Q43075860-5FF107FB-98F8-491A-A105-5DF4C37654DD
P2860
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
description
1990 nî lūn-bûn
@nan
1990 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@ast
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@en
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@nl
type
label
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@ast
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@en
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@nl
prefLabel
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@ast
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@en
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@nl
P2093
P1476
Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
@en
P2093
R C Thompson
S P Eisenberg
P304
P407
P577
1990-05-15T00:00:00Z